Community

Start with your question. Search first, choose the closest subject and keep personal details private. Posting guidelines
Notifications
Clear all

July 1st 503b concerns

1 Posts
1 Users
0 Reactions
174 Views
GarnetHouse
(@garnethouse)
Eminent Member
Joined: 6 years ago
Posts: 16
Topic starter   [#24090]

Bloodwork question about AOD-9604. Baseline, three years in, and the numbers moved in a direction I did not expect.

If you need three other compounds to notice the first one, you have not tested the first one.

What the peptide class does pharmacologically does not require the subjective effect to be large to be real.

The comparison group matters more than the compound when the outcome is something as fuzzy as focus.

Animal data is much of what exists here and the human stuff is thin and small.

Anyone got a paper worth reading on this rather than a write-up of a paper?



   
Quote
Share: